ReviewCurrent rheumatology reports2015
Advances in the evaluation and management of esophageal disease of systemic sclerosis.
Review in Current rheumatology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Changes on Nailfold Video Capillaroscopy Associate With High-Resolution Esophageal Manometry Findings in Patients With Scleroderma.Gastro hep advances · 2026Review
- Mangiferin Against Respiratory Diseases: Pharmacological Targets and Prospects.Pharmacology research & perspectives · 2025Review
- Gastroesophageal Intussusception Treated With Combined Transoral Incisionless Fundoplication in a Patient With Systemic Sclerosis.ACG case reports journal · 2025Article
- Expanding Training Data for Endoscopic Phenotyping of Eosinophilic Esophagitis.Proceedings of SPIE--the International Society for Optical Engineering · 2025Article
- Managing gastrointestinal manifestations in systemic sclerosis, a mechanistic approach.Expert review of clinical immunology · 2024Review
- Associations Between Patterns of Esophageal Dysmotility and Extra-Intestinal Features in Patients With Systemic Sclerosis.Arthritis care & research · 2023Article
- Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease.The Lancet. Rheumatology · 2022Article
- Management of scleroderma gastrointestinal disease: Lights and shadows.Journal of scleroderma and related disorders · 2022Review
- A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis.Best practice & research. Clinical rheumatology · 2021Review
- Esophageal manifestation in patients with scleroderma.World journal of clinical cases · 2021Review
- Estimation of mechanical work done to open the esophagogastric junction using functional lumen imaging probe panometry.American journal of physiology. Gastrointestinal and liver physiology · 2021Article
- Mast Cell Activation in the Systemic Sclerosis Esophagus.Journal of scleroderma and related disorders · 2021Article
- Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).Annals of the rheumatic diseases · 2021Review
- Article
- Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis.Medical research archives · 2020Article
- GI Manifestations With a Focus on the Esophagus: Recent Progress in Understanding Pathogenesis.Current rheumatology reports · 2019Review
- Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value.Clinical rheumatology · 2018Article
- Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients.Neurogastroenterology and motility · 2018Article
- Dysphagia: Thinking outside the box.World journal of gastroenterology · 2017Review
- The Videofluorographic Swallowing Study in Rheumatologic Diseases: A Comprehensive Review.Gastroenterology research and practice · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Symptoms of heartburn and dysphagia as well as objective findings of abnormal esophageal acid exposure and esophageal dysmotility are common in patients with systemic sclerosis (SSc). Treatments for SSc esophageal disease are generally limited to gastroesophageal reflux disease (GERD) treatment with proton pump inhibitors. Progresses made in esophageal diagnostic testing offer the potential for improved clinical characterization of esophageal disease in SSc that may help direct management decisions. In addition to reviewing GERD management in patients with SSc, present and potential uses of endoscopy, reflux monitoring, manometry, impedance planimetry, and endoscopic ultrasound are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.